Cuál es el precio por Affimed N.V. (AFMD)

Precio por Affimed N.V. (AFMD) es de$0.1815

Cuál es la capitalización de mercado por Affimed N.V. (AFMD)

Capitalización de mercado por Affimed N.V. (AFMD) es $2.78M

Affimed N.V. (AFMD) Historial de Precios

Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa clinical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.

Año	Rendimiento
2026 (TTM)	0.83%
2025	-90.07%
2024	-57.88%
2023	-70.32%
2022	-75.20%
2021	-6.12%
2020	142.60%
2019	-25.12%
2018	134.16%
2017	-23.40%
2016	-73.12%
2015	13.03%
2014	0.00%

Año

Rendimiento

2026 (TTM)

0.83%

2025

-90.07%

2024

-57.88%

2023

-70.32%

2022

-75.20%

2021

-6.12%

2020

142.60%

2019

-25.12%

2018

134.16%

2017

-23.40%

2016

-73.12%

2015

13.03%

2014

0.00%

Empresa	Precio de la acción	Cambio 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$505.24	28.63%	US
Argenx SE ARGX.US	$846.09	29.41%	NL
Lonza Group AG LONN.SW	$731.69	6.47%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$251.82	11.75%	BE

Empresa

Precio de la acción

Cambio 1a%

País